Ikarian Capital, LLC Crispr Therapeutics Ag Call Options Transaction History

Ikarian Capital, LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $149,111 - $278,686	3,861 Added 9900.0%	3,900 $244,000
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $9.08 Million - $11.8 Million	-199,961 Reduced 99.98%	39 $1,000
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $8.69 Million - $13.6 Million	200,000 New	200,000 $11.2 Million

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.